San Diego-primarily based Viking Therapeutics marked itself as a serious competitor in the weight loss drug market in February soon after revealing promising facts from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given like a weekly injection As well as in March the company